Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

LAVA Therapeutics N.V. - Ordinary Shares (NQ:LVTX)

1.740 UNCHANGED

Last Price Updated: 4:00 PM EST, Nov 20, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	1.740
Bid (Size)	1.610 (5,000)
Ask (Size)	1.850 (100)
Prev. Close	1.740
Today's Range	1.740 - 1.740
52wk Range	1.030 - 1.825
Shares Outstanding	26,289,087
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

November 21, 2025

From XOMA Royalty Corporation

Via GlobeNewswire

LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty ↗

October 17, 2025

As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon.

Via Stocktwits

Performance

YTD	N/A	N/A
1 Month	N/A	N/A
3 Month	N/A	N/A
6 Month	+18.4%	+18.4%
1 Year	+31.8%	+31.8%

More News

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

October 17, 2025

From XOMA Royalty Corporation; LAVA Therapeutics N.V.

Via GlobeNewswire

LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting ↗

September 30, 2025

Via Stocktwits

Thursday's after hours session: top gainers and losers ↗

October 02, 2025

Via Chartmill

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

October 02, 2025

From XOMA Royalty Corporation; LAVA Therapeutics

Via GlobeNewswire

4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week ↗

September 03, 2025

Via Benzinga

This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

August 05, 2025

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)

August 04, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders

August 04, 2025

From Halper Sadeh LLC

Via Business Wire

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

August 04, 2025

From XOMA Royalty Corporation; LAVA Therapeutics N.V.

Via GlobeNewswire

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang ↗

February 28, 2025

Via Benzinga

This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

February 27, 2025

Via Benzinga

On Wednesday, there are stocks with unusual volume. Let's take a look. ↗

February 26, 2025

Via Chartmill

What's going on in today's session ↗

February 25, 2025

Via Chartmill

Which stocks are experiencing notable movement on Tuesday? ↗

February 25, 2025

Via Chartmill

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

February 25, 2025

Via Chartmill

LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024 ↗

August 20, 2024

Via InvestorPlace

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

June 20, 2024

From LAVA Therapeutics N.V.

Via GlobeNewswire

LAVA Announces Annual Meeting of Shareholders

June 10, 2024

From LAVA Therapeutics N.V.

Via GlobeNewswire

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 30, 2024

From LAVA Therapeutics N.V.

Via GlobeNewswire

LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗

May 21, 2024

Via InvestorPlace

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

May 21, 2024

From LAVA Therapeutics N.V.

Via GlobeNewswire

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

May 06, 2024

From LAVA Therapeutics N.V.

Via GlobeNewswire

LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023 ↗

March 20, 2024

Via InvestorPlace

Frequently Asked Questions

Is LAVA Therapeutics N.V. - Ordinary Shares publicly traded?

Yes, LAVA Therapeutics N.V. - Ordinary Shares is publicly traded.

What exchange does LAVA Therapeutics N.V. - Ordinary Shares trade on?

LAVA Therapeutics N.V. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for LAVA Therapeutics N.V. - Ordinary Shares?

The ticker symbol for LAVA Therapeutics N.V. - Ordinary Shares is LVTX on the Nasdaq Stock Market

What is the current price of LAVA Therapeutics N.V. - Ordinary Shares?

The current price of LAVA Therapeutics N.V. - Ordinary Shares is 1.740

When was LAVA Therapeutics N.V. - Ordinary Shares last traded?

The last trade of LAVA Therapeutics N.V. - Ordinary Shares was at 11/20/25 04:00 PM ET

What is the market capitalization of LAVA Therapeutics N.V. - Ordinary Shares?

The market capitalization of LAVA Therapeutics N.V. - Ordinary Shares is 45.74M

How many shares of LAVA Therapeutics N.V. - Ordinary Shares are outstanding?

LAVA Therapeutics N.V. - Ordinary Shares has 46M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.